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ADP    Adenosine diphoshate 
ATP    Adenosine triphoshate 
BSA    Bovine Serum Albumin 
cDNA    Complementary DNA 
DAPI    4',6-Diamidino-2-phenylindole 
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PVDF    Polyvinylidene difluoride 
RNA    Ribonucleic acid 
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siRNA    small interfering RNA 
TBE    Tris borate-EDTA buffer 
TBS    Tris-buffered saline 
TBST    Tris-buffered saline Tween® 20 
TBSTM   Tris-buffered saline Tween® 20 plus milk 
TRF-1    TTAGGG repeat binding factor 1 
v/v    Volume to volume ratio 
VPARP   Vault PARP 
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1. INTRODUCTION 
 
1.1 RNA interference (RNAi) 
RNA interference is a gene regulatory mechanism that limits transcript levels 
by activating a sequence-specific RNA degradation process. RNAi and related 
processes represent evolutionarily conserved mechanisms, which protect organisms 
from invasion by both exogenous (e.g., viruses) and endogenous (e.g., mobile 
genetic elements) genetic parasites. In addition, dsRNA-dependent silencing 
represents a conserved regulatory motif for endogenous programs of gene 
expression. We are just beginning to understand not only the biological roles of RNAi 
but also the mechanistic basis of this process. 
 
The first definitive demonstration that RNA could trigger gene silencing came 
from the discovery of RNAi in C. elegans. In an attempt to use antisense RNA to 
investigate gene function in C. elegans, Guo and Kemphues observed that injection 
of either antisense or sense RNAs into the syncitial germline of worms was equally 
effective at silencing homologous target genes (Guo and Kemphues 1995). As an 
extension of these experiments, Mello and Fire tested whether combination of sense 
and antisense RNAs might enhance the effect (Fire et al. 1998). The result was 
startling. Combined sense and antisense, in essence double-stranded RNA, was an 
incredibly potent silencer of gene expression. The dsRNA mixture was at least 10 
times more effective than either sense or antisense RNAs alone. 
 
From this discovery emerged the notion that a number of previously 
characterized, homology-dependent gene-silencing mechanisms might share a 
common biological root. Several years previously, Richard Jorgensen had been 
engineering transgenic petunias with the goal of altering pigmentation, but 
introducing exogenous transgenes did not deepen flower pigmentation: in many of 
the plants the result was the opposite, white or irregularly coloured petunia petals 
(Jorgensen 1990). This indicated that not only were the transgenes themselves 
inactive, but also that the added DNA sequences somehow affected expression of 
the endogenous loci. This apparent communication between unlinked but 
homologous loci was termed co-suppression.  
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Co-suppression phenomena are not restricted to plants: similar outcomes 
have been noted in unicellular organisms, such as Neurospora, and in metazoans, 
such as Drosophila, C. elegans and mammals (Romano and Macino 1992, Fire et al. 
1991, Pal-Bhadra et al. 1997). 
Genetic and biochemical studies have now confirmed that RNAi and co-
suppression share mechanistic similarities and that the biological pathway underlying 
dsRNA-induced gene silencing exists, in many, if not most, eukaryotic organisms.  
 
1.1.1 Mechanism of RNAi 
The precise mechanisms behind RNAi are not yet fully understood, but in the 
last few years, important insights have been gained in elucidating key aspects of the 
RNAi process. RNAi mediated by the introduction of long dsRNA is a two step 
mechanism (Fig. 1). 
 
The initiation step 
Initiation of silencing occurs upon recognition of dsRNA by a machinery that 
converts the silencing trigger to ~21-25 nucleotide RNAs (small interfering RNAs, 
siRNA). In Drosophila it was shown that a class of RNase III enzymes produces 
siRNA from long dsRNAs in an ATP-dependent manner (Bernstein et al. 2001). 
These enzymes – named DICERS – are evolutionarily conserved in organisms 
competent for RNAi. Structural information has led to a model in which Dicer 
functions as an anti-parallel dimer to form ∼22mer siRNAs (Hannon 2002). Cleavage 
into precisely sized fragments is determined by the fact that one of the active sites in 
each Dicer protein is defective, shifting the periodicity of cleavage from ~9-11 
nucleotides for bacterial RNase III to ~22 nucleotides for Dicer. 
 
The effector step 
The small interfering RNAs (siRNAs) are signature of RNA interference. They 
are double-stranded duplexes with two-nucleotide 3`overhangs and 5`-phosphate 
termini (Zamore et al. 2000; Elbashir et al. 2001b) and serve as a sequence-based 
template for recognition by RISC (RNA-induced silencing complex), a protein-RNA 
effector nuclease complex that recognizes and destroys target mRNAs. The siRNAs 
are incorporated into the multicomponent nuclease RISC. Recent reports suggest 
that RISC must be activated from a latent form, converting a double-stranded siRNA 
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to an active form by unwinding of siRNAs (Nykanen et al. 2001). RISC then uses the 
unwound siRNA through Watson-Crick basepairing as a guide to substrate selection 
(Hammond et al. 2000) and the specific target mRNAs are degraded. 
 
 
Figure 1: A model for the mechanism of RNA interference.  
(Modified from Hannon, 2002) 
 
 
 
1.1.2 Systemic silencing and amplification 
One of the most provocative and least understood aspects of dsRNA-induced 
gene silencing is its ability to spread throughout certain organisms. This property is 
most evident in C. elegans and in plants. 
In plants the silencing information is transmitted throughout the plant via the 
plant’s macromolecular trafficking system, which is composed of cell-to-cell transport 
via plasmodesmata and long-distance transport via the phloem translocation system 
(Palauqui et al. 1997; Voinnet et al. 1998). When the silencing effect is induced by a 
virus, this process of spreading leads to resistance to the virus in regions of the plant 
where the virus is not yet active, protecting the plant from further virus infection. But 
plants are not the only phylum in which systemic silencing effects have been 
observed. 
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The effects of dsRNA can also spread to tissues in which it has not been 
directly introduced in C. elegans (Fire et al. 1998). For example, one can feed E. coli 
that produces dsRNA encoded by a plasmid to C. elegans. This will lead to a very 
robust RNAi response not only in the fed animal itself, but also in its progeny 
(Timmons and Fire 1998). 
Obviously, the question regarding systemic RNAi is: How does the dsRNA 
spread throughout the animal? Are there specialized transport routes for dsRNA, or is 
it taken up through more general pathways that are also used for the uptake of 
nutrients? In C. elegans, a putative transmembrane protein, SID-1 (systemic RNAi-
deficient), was shown to be important for systemic RNAi (Winston et al. 2002). The 
sid-1 gene is required to spread gene-silencing information between tissues but not 
to initiate or maintain an RNAi response. SID-1 homologues are absent from 
Drosophila, consistent with a lack of systemic transmission of silencing in flies, 
whereas the strong similarity to predicted human and mouse proteins suggest the 
possibility that RNAi is systemic in mammals (Winston et al. 2002). Further molecular 
characterization of sid-1 and other loci will undoubtedly lead to a better 
understanding of this systemic silencing process. 
Screens for genes required for gene silencing in plants, fungi, and worms have 
identified a family of proteins whose sequences suggest they are RNA-dependent 
RNA polymerases (RdRPs) (Cogoni and Macino 1999; Dalmay et al. 2000; Mourrain 
et al. 2000; Sijen et al. 2001). The discovery of RdRPs in RNAi provides a possible 
explanation for the remarkable efficiency of dsRNA in gene silencing in these 
organisms. New dsRNA could be synthesized by RdRP and thus amplify the 
silencing process. In D. melanocaster and mammals, RdRP genes have not been 
identified by database analysis. 
 
 1.1.3 RNAi as a tool in mammalian cells 
RNAi has evolved into a powerful tool for probing gene function, although it 
seemed for some time that developing RNAi in mammalian systems would not be 
feasible because mammalian somatic cells exhibit nonspecific responses to dsRNA 
which would obscure sequence-specific silencing. One of these is the RNA-
dependent protein kinase (PKR) pathway, which phosphorylates and inactivates the 
translation factor eIF2α, leading to a generalized suppression of protein synthesis 
and cell death via both non-apoptotic and apoptotic pathways (Clemens and Elia 
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1997). A second dsRNA-response pathway involving the dsRNA-induced activation 
of a sequence-nonspecific RNase (RNase L) has also been demonstrated (Player 
and Torrence 1998). 
One way to overcome these nonspecific dsRNA responses is to simply create 
dsRNA triggers of < 30 bp in length because the activation of PKR by dsRNA has 
been shown to be length-dependent; dsRNAs of less than 30 nucleotides are unable 
to aktivate PKR, and full activation requires ~80 nucleotides (Minks et al. 1979; 
Manche et al. 1992). 
Elbashir et al. (2001a) and Caplen et al. (2001) first demonstrated that small 
dsRNAs, resembling siRNAs from other systems, induce sequence-specific gene 
silencing when transiently transfected into mammalian cells. The siRNAs presumably 
bypass the requirement for Dicer and enter the silencing pathway by incorporation 
into RISC complexes. 
As an alternative strategy, in vivo expression constructs for small dsRNA 
triggers, which resemble endogenously expressed hairpin RNAs, can be delivered to 
mammalian cells (Brummelkamp et al. 2002a; Paddison et al. 2002b). This approach 
uses small inverted repeats (19-29 nt) expressed from RNA polymerase III promoter 
to create short hairpin RNAs (shRNAs), which can then be processed by Dicer and 
shunted into the RNAi pathway. 
 
1.1.4 Transient and stable RNAi 
To knock down target genes in mammalian cells, chemically synthesized 21-nt 
siRNA duplexes were first used (Caplen et al. 2001; Elbashir et al. 2001a). siRNA 
can also be transcribed in vitro with T7 RNA polymerase, and such siRNA is as 
effective as chemically synthesized siRNA (Donze and Picard 2002; Yu et al. 2002).  
To obtain stable transfection in cells and animals, DNA expression vector-based 
siRNAs have been developed. In this strategy, a short hairpin RNA (shRNA) is 
generated in cells under the control of an RNA polymerase III (U6) promoter 
(Brummelkamp et al. 2002a). 
However, the efficiency of siRNA is dependent on the identification of specific 
target sites because not all sequences are effective in RNA-mediated silencing. To 
date, the selection of siRNA sequences is still empirical although a few rules can be 
followed. Generally, several siRNAs derived from different regions of a target mRNA 
need to be tested in order to achieve an efficient siRNA. Therefore the direct use of 
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siRNAs for screening of efficiency is warranted. However, a significant disadvantage 
of this system is that the effects are transient, with phenotypes generated by 
transfection with such RNAs persisting for 1 week or even less. 
In contrary, short hairpin RNAs, generated in vivo from expression vectors are 
potent experimental tools for inducing gene silencing in mammalian somatic cells 
over long term periods. Not only does this enable the creation of continuous cell lines 
in which suppression of a target gene is stably maintained by RNAi, but similar 
strategies may also be useful for the construction of transgenic animals. Thus, short-
hairpin-activated gene silencing provides a complement to the use of siRNA in the 
study of gene function in mammalian cells. 
Finally, the ability to encode a constitutive silencing signal may permit the 
marriage of dsRNA-induced silencing with in vivo and ex vivo gene delivery methods 
for therapeutic approaches based on stable RNAi in mammals. 
 
1.1.5 Gene-silencing in therapeutic intervention 
The ability of small-interfering RNAs to silence gene expression in somatic 
mammalian cells has provided researchers with a novel tool to block the expression 
of disease-causing genes, provided that their mRNA sequences are known. siRNA 
technology can be applied to a wide range of cancers and other proliferative 
disorders in which aberrant gene expression occurs. But for the time being, most of 
the clinical interest lies in applying RNAi in its natural role: as a means of combating 
pathogenic viruses by disabling their RNA. 
Efficient delivery of siRNAs in vivo remains, however, a crucial challenge for 
successful transition from the laboratory to the clinic. Researchers are exploring a 
variety of ways to solve this problem.  
Generally, synthetic siRNAs are delivered to cells in culture via liposome-
based transfection reagents. However, only a few of these lipids have been shown to 
facilitate the uptake of nucleic acids in vivo (Safinya 2001) and possible toxic side-
effects must be considered. 
In chronic diseases, for example, long-term biological effects are desired. 
Delivery of siRNA can therefore be achieved via a gene therapy approach that relies 
on the endogenous expression of siRNA from plasmid or viral vectors. Safety issues 
and the toxicity of these vectors will probably hamper their use in animals or humans 
(Thomas et al. 2003). Thus, improved viral-based vectors to overcome some 
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unwanted side-effects are required before the true clinical benefits of RNAi-based 
therapies can be realized.  
And last but not least, another important question mark hanging over the 
therapeutic use of RNAi is its specificity. Although the actual substrate specificity of 
individual siRNAs appears to be very high (Elbashir et al. 2001a; Brummelkamp et al. 
2002a), recent studies indicate that siRNAs can tolerate single mutations located in 
the centre of the molecule, and up to four mutations are necessary for complete 
inactivation (Holen et al. 2002; Jacque et al. 2002; Leirdal and Sioud 2002). 
To examine the specificity of siRNAs, global gene expression has been 
investigated by Semizarov and colleagues using microarray technology (Semizarow 
et al. 2003). At high concentrations, siRNAs non-specifically induced the expression 
of a significant number of genes, many of which are known to be involved in 
apoptosis and stress response. However, reduction of the siRNA concentration 
eliminated this non-specific response.  
Although the recent preclinical studies present compelling data on the utility of 
siRNA in disease models, we will not know the exact potential that RNAi afford for 
treating diseases until suitable delivery methods are established to enable the 
performance of clinical trials. A second key issue is the specificity of siRNAs, and the 
impact that this might have on their safety in animals and humans. 
 
However this fast-moving field is going on, the goal of this work is to use RNAi 
as a powerful tool to study the functions of poly(ADP-ribose) polymerases (PARPs).  
 
1.2 Poly(ADP-ribosyl) ation 
Poly(ADP-ribosyl) ation is a post-translational modification of proteins. During 
this process, molecules of ADP-ribose are added successively onto acceptor proteins 
to form branched polymers. The existence of poly(ADP-ribose) was first reported 
nearly 40 years ago. Since then, the importance of poly(ADP-ribose) synthesis has 
been established in many cellular processes.  
The synthesis of ADP-ribose requires three distinct enzymatic activities: 1. 
initiation or mono(ADP-ribosyl) ation of the substrate; 2. elongation of the polymer 
and; 3. branching of the polymer (Fig. 2). 
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 Figure 2: Poly(ADP-ribosyl) ation (Rouleau et al. 2004) 
 
 
A family of enzymes known as poly(ADP-ribose) polymerases (PARPs) 
possess all these three activities. 
The constitutive levels of polymer are usually very low in unstimulated cells. 
The majority of the ADP-ribose units found on acceptor proteins in the absence of 
DNA damage appear as mono- or oligo (ADP-ribose). They are qualitatively different 
from those synthesized in the presence of DNA damage, and their degradation is far 
slower than that of polymers synthesized in response to genotoxic agents. 
In the presence of DNA strand breaks, the activity of PARP-1, the most 
abundant member of the PARP family, and the levels of ADP-ribose polymers can be 
increased several fold (Wielckens et al. 1983; Alvarez-Gonzalez and Althaus 1989; 
Simonin et al. 1993), while cellular NAD+ levels are correspondingly reduced (Singh 
et al. 1985). In living cells, the synthesis of poly(ADP-ribose) is directly proportional to 
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the number of single- and double-strand breaks present in genomic DNA (Althaus 
and Richter 1987). 
These observations have led to the idea that PARP-1 might act as a 
“molecular nick sensor”; PARP-1 recognizes and rapidly binds to DNA strand breaks 
through its zinc fingers and, in turn, its catalytic domain is allosterically activated and 
starts to synthesize complex branched poly(ADP-ribose) chains. The result is the 
automodification of PARP-1 itself and, to a lesser extent, the modification of other 
proteins, including histones.  
More than 30 nuclear substrates of PARP-1 have been identified in vivo and in 
vitro (Althaus and Richter 1987). However following genotoxic stress, the main 
acceptor of ADP-ribose in vivo is PARP itself (Ogata et al. 1981). Modification of 
proteins and PARP-1 itself at the site of DNA strand breaks favours the repair 
process and acts as a strong signal for the recruitment of DNA damage-signalling 
molecules (Althaus 1992; Althaus et al 1999).   
 
Reversibility: PARG and the catabolism of PAR 
Like other covalent protein modifications (e.g. phosphorylation, acetylation), 
poly(ADP-ribosyl) ation is reversible (Amé et al. 2000; D’Amours et al. 1999). The 
efficient degradation of poly(ADP-ribose) requires three different enzymatic activities, 
which are carried out by two distinct enzymes: poly(ADP-ribose) glycohydrolase 
(PARG) and ADP-ribosyl protein lyase. The existence of PARG was first 
demonstrated by Miwa and Sugimura (1971) and by Ueda et al. (1972). Human and 
bovine PARG cDNA have been cloned, and were shown to encode proteins of 111 
kDa (Lin et al. 1997). PARG possesses exoglycosidase (Miwa et al. 1974) and 
endoglycosidase (Ikejima and Gill 1988) activity. These activities are responsible for 
the hydrolysis of glycosidic bonds between ADP-ribose units located at the extremity 
and within the polymer, respectively.  
ADP-ribosyl protein lyase is the enzyme responsible for the hydrolysis of the 
most proximal unit of ADP-ribose on the protein acceptor.  
In vivo, the steady-state cellular levels of poly(ADP-ribosyl)ation are 
determined by the opposing actions of PARPs and PARG (Davidovic et al. 2001). 
PARG activity appears to increase proportionally with polymer size, allowing PARG 
to counteract the actions of PARP more effectively for long polymers. 
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Once freed from the polymer, ADP-ribose units are catabolized to AMP and 
ribose 5’-phosphate by (ADP-ribose) pyrophosphatases (Miro et al. 1989; Fernandez 
et al. 1996). 
 
1.2.1 PARP-1 structure 
PARP-1 (113 kDa) is an abundant nuclear protein found in all eukaryotes 
except yeast. 
In the late 1980’s the cloning of the human PARP gene allowed its localization 
on chromosome 1 and established that it consists of 23 exons spanning 
approximately 42 kb of DNA (Cherney et al. 1987). The same organization was found 
for the murine gene, albeit spanning only 33 kb (Berghammer et al. 1992). The gene 
codes for a protein of 1014 amino acids which has been isolated in high levels from 
testis, thymus and spleen, while lower levels were found in liver, kidney and heart. 
On the subcellular level, PARP is present primarily in the nucleus, albeit with non-
homogeneous distribution. 
  
The primary structure of PARP-1 consists of four main distinct regions: 
1. A N-terminal DNA-binding domain (DBD) bearing two zinc fingers (FI, FII) acting 
both as a molecular nick sensor and as an interface for interaction with protein 
partners 
2. A bipartite nuclear location signal interrupted by a caspase-3 cleavage site, at 
which PARP-1 is cleaved during apoptosis. 
3. A central automodification domain containing a BRCT motif involved in protein-
protein interactions. This region also contains auto-poly(ADP-ribosyl)ation sites 
implicated in the negative regulation of PARP-DNA interactions. 
4. A C-terminal catalytic domain containing a donor site (NAD+binding) and an 
acceptor site (polymer binding). This domain, highly conserved during evolution, 
is responsible for poly(ADP-ribose) synthesis. 
 
The primary structure of PARP-1 presents high interspecies homology, with 
human and mouse variants sharing 92% homology. The C-terminal part, and 
particularly residues 859 to 908, represents the most highly conserved region among 
PARPs (Fig. 3). This amino acid stretch has therefore been termed the “PARP 
signature sequence”. 
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Figure 3: Schematic structure of six different members of the PARP family. 
Percentages indicate the amino acid identities to PARP-1 (Modified from Smith, 
2001). 
 
 
 
1.2.2 Biological roles of PARP-1 
PARP-1 and DNA transcription  
Poly(ADP-ribosyl)ation participates in the regulation of transcriptional activity. 
The available data suggest that PARP-1’s activity in transcriptional regulation occurs 
by at least two mechanisms that are not mutually exclusive: 1. modifying histones to 
alter chromatin structure and 2. functioning as part of enhancer/promoter binding 
complexes in conjunction with other DNA binding factors and coactivators. 
Poly(ADP-ribosyl) ation of histones contributes to the transcription-promoting 
effect of PARP-1. In fact poly(ADP-ribose) confers negative charges to histones, 
leading to electrostatic repulsion between histones and DNA. Thus, poly(ADP-ribosyl) 
ation can loosen the chromatin structure and can thereby make genes more 
accessible for the transcriptional machinery (D’Amour et al. 1999).  
In addition, PARP-1 activity at enhancers and promoters is mediated in large 
part by functional interactions between PARP-1 and various non-histone proteins, 
many of which are DNA binding transcription factors, including NF-κB (Hassa and 
Hottiger 1999), p53 (Whitacre et al. 1995), B-MYB (Cervellera and Sala 2000), and 
nuclear receptors (Miyamoto et al. 1999), to name some of them.  
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PARP-1 modulates gene expression in both a positive and a negative fashion, 
with the final effects depending on the cell type, the gene and the transcription factor 
involved (Ziegler and Oei 2001). 
 
PARP-1 and the maintenance of genomic stability 
PARP-1 has been implicated in DNA-repair and maintenance of genomic 
integrity (de Murcia and Menissier de Murcia 1994; Schreiber et al. 1995). This 
“guardian angel” function is indicated by delayed DNA base-excision repair and by a 
high frequency of sister chromatid exchange (SCE) in PARP-1-deficient cells 
exposed to ionizing radiation or treated with alkylating agents (de Murcia et al. 1997). 
For the PARP knockout studies, the frequency of SCE was 2-5 fold higher either 
before or after DNA damage. In addition to an increased SCE frequency, PARP-1 
knockout cells contain increased levels of micronuclei after DNA damage (Wang et 
al. 1997). PARP-1 null mutation in mice causes also high levels of aneuploidy, 
chromosomal fragmentation and fusion as well as chromosome loss and gain 
(d`Adda di Fagagna et al. 1999; Tong et al. 2001; Simbulan-Rosenthal et al. 1999). 
These data together demonstrate that PARP-1 acts as a genome guardian molecule. 
 
Poly(ADP-ribosyl) ation, NAD+ metabolism and cell death  
Paradoxically, despite the beneficial effect in the maintenance of genomic 
stability, PARP-1 can induce cell death through NAD+ depletion.  
It is well established that excessive DNA damage causes PARP-1 hyperactivation, 
which in turn depletes NAD+ pools within only a few minutes (D`Amour et al. 1999; 
Shall and de Murcia 2000). Consequently, the main NAD+-dependent metabolic 
pathways such as glycolysis and mitrochondrial respiration are impaired, leading to 
reduced ATP production and cellular dysfunction. Moreover, under these conditions 
phosphoribosyl pyrophosphate synthetase and nicotinamide mononucleotide 
adenylyl transferase consume ATP in effort to resynthesize NAD+, worsening the 
energetic shortage and contributing to the generation of a lethal, futile cycle. This 
pathway is identified as a causal event of necrotic cell death. 
 
Role of poly(ADP-ribosyl) ation in disease 
The use of PARP-1 knockout mice and selective PARP inhibitors in various 
models of disease has provided interesting insights at what might be the role of the 
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enzyme’s activation. When overactivation of PARP-1, which leads to energy-
depletion by consumption of NAD+ levels, takes place on the scale of an organ (e.g., 
during the ischemia and reperfusion of the brain or the heart), necrosis on a large 
scale leads to the loss of organ function and ultimately to death. 
Therefore PARP-1 has been implicated in the pathogenesis of several diseases that 
are characterized by excessive PARP-1 activity, like stroke, myocardial ischemia, 
diabetes, diabetes-associated cardiovascular dysfunction, shock, traumatic central 
nervous system injury, arthritis, colitis, allergic encephalomyelitis, and various other 
forms of inflammation. 
Accordingly, the inhibition of PARP-1 activity is a valid therapeutic strategy in a 
wide number of experimental disorders and has been a field of intense investigation 
for both basic scientists and pharmaceutical companies.  
 
1.2.3 The PARP family 
The first hint of the presence of more than one PARP enzyme existing in cells 
came from the observation of poly(ADP-ribose) synthesis in mouse embryonic 
fibroblasts derived from PARP-1 knockout mice (Shieh et al. 1998). Since then 
numerous reports have appeared describing new members of a still expanding 
family. At the time of this writing, the family consists of 18 PARP proteins; 6 of them 
are more or less well characterized.  
 
PARP-2 
In 1999, Amé et al. described the isolation and characterization of a new 
member of the family, named PARP-2 (Amé et al. 1999). 
The PARP-2 gene maps to chromosome 14C1 and 14q11.2 in mouse and 
human, which are distinct from PARP-1 loci, supporting the conclusion that PARP-2 
is coded by a different gene. 
PARP-2 bears a strong resemblance to PARP-1. An alignment of the 
sequences showed that the carboxy-terminal region of PARP-2 shared 43% identity 
with PARP-1. This sequence contains the PARP signature, i.e. the ADP-ribose donor 
site and the crucial residues of the acceptor site. 
PARP-2 (like PARP-1) is a nuclear protein that binds to and is activated by 
DNA strand breaks (Amé et al. 1999). Interestingly the DNA-binding domain of 
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PARP-2 is distinct from PARP-1 and could indicate different substrate specificities 
and possibly different functional roles for these two proteins. Nonetheless, it is likely 
that PARP-2 contributes to the residual poly(ADP-ribose) synthesis observed in 
PARP-1-/- cells after treatment with DNA-damaging agents. 
 
PARP-3 
PARP-3 is a 533 amino acid nuclear protein with a mass of 60.1 kDa 
(Johannsson et al. 1999). It consists of a unique N-terminal domain of 39 amino 
acids, followed by the PARP homology domain. Recombinant hPARP-3 localizes in 
vitro during the entire cell cycle to the centrosome, the microtubule organizing centre 
of animal cells, and resides preferentially in the daughter centriole. hPARP-3 has 
been shown to negatively influence the G1/S cell cycle progression without interfering 
with centrosome duplication (Augustin et al. 2003). The presence of both PARP-1 
and PARP-3 at the centrosome may link the DNA damage surveillance network to 
the mitotic fidelity checkpoint but future studies are necessary to reveal the specific 
functions of PARP-3. 
 
VPARP 
VPARP or PARP-4 was identified as a component of the vault complex. The 
vault complexes are with a mass of 13 MDa the largest ribonucleoprotein particles 
described to date. Vaults are barrel-shaped cytoplasmic particles that are composed 
of a major vault protein (MVP), two minor vault proteins [telomerase-associated 
protein 1 (TEP1), vault poly(ADP-ribose) polymerase (VPARP)] and small 
untranslated RNA molecules.  
The function of these unusual particles is unknown; however, their subcellular 
localization and distinct morphology point to a role for vaults in intracellular, 
particularly nucleo-cytoplasmic, transport (Abbondanza et al. 1998; Li et al. 1999). 
Unique features of VPARP are a BRCA1 C-terminus (BRCT) domain (aa1-94) and an 
inter-α-inhibitor domain (aa616-1195); both domains may be involved in protein-
protein interactions. The C-terminus of VPARP (aa1562-1724) has been shown to 
associate with the N-terminal part of MVP (Kickhoefer et al. 1999; van Zon et al. 
2002). 
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Immunofluorescence and biochemical fractionation studies clearly indicate that 
not all VPARP is bound to vaults. VPARP is also present in the nuclear matrix and in 
cytoplasmic clusters (VPARP-rods) (Kickhoefer et al. 1999; Schroeijers et al. 2000). 
Vault poly (ADP-ribose) polymerase exhibits a poly (ADP-ribose) polymerase activity 
and can poly (ADP-ribosylate) MVP and to a lesser extent, itself (Kickhoefer et al. 
1999). Whether there are other substrates of VPARP is presently unknown. It is also 
not yet clear whether VPARP fulfils separate functions – unrelated to vault function – 
in its non-vault associated form. 
 
Tankyrase 1 
Tankyrase, also known as PARP-5, is a 142 kDa protein that has been 
localized to the human telomers (Smith et al. 1998). Telomeres, which are essential 
for chromosome maintenance and stability, are maintained by telomerase, a 
specialized reverse transcriptase. 
Tankyrase was initially identified through its interaction with TRF1, a negative 
regulator of telomere length (van Steensel and de Lange 1997). Tankyrase was 
found to poly(ADP-ribosyl) ate itself and TRF1 and this modification inhibited the 
binding of TRF1 to telomeric RNA (Smith et al. 1998). 
Overexpression of tankyrase affects TRF1 at telomeres and promotes 
telomere elongation in human cells (Smith and de Lange 2000), indicating that 
tankyrase can function as a telomere-length regulator. 
 
Tankyrase 2 
In 2000, studies revealed a tankyrase homolog, termed tankyrase 2 (Chi and 
Lodish 2000), which exhibits more than 80% identity with tankyrase. The localization 
and function of this tankyrase homolog is not yet known. 
 
1.3 Aim of this work 
PARP-1 and PARP-2 are both involved in the response to DNA damage. 
However a specific female embryonic lethality has been identified in PARP-1+/- 
PARP-2-/- mice associated with X-chromosome instability, suggesting that the two 
enzymes have both non-redundant and overlapping functions in the maintenance of 
genomic stability.  
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The fact that there exist more than one PARP protein in the cells and that PARP-1-/- 
PARP-2-/- mice are not viable makes it difficult to characterize the distinctive functions 
of PARP-1 and PARP-2. Based on this knowledge, the aim of this work was to set up 
the best conditions for a knockdown of PARP-1 by RNA interference using either in 
vitro transcribed siRNA molecules or a plasmid vector producing the siRNA 
molecules within the cells. The knockdown of PARP-1 expression in mammalian cells 
will be the basis for further work to elucidate the distinct functions of the enzymes 
PARP-1 and PARP-2. 
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2. MATERIALS 
________________________________________________________________ 
 
2.1 Cell culture  
Cell culture medium, Dulbecco`s Modified Eagle`s Medium (DMEM), fetal 
bovine serum, antibiotics (as Penicillin-Streptomycin mixture) and trypsin-EDTA were 
all purchased from GibcoBRL; Invitrogen, Carlsbad, CA, USA). 
 
2.2 Chemicals, enzymes and plasmids 
GFP-p53 plasmid was purchased from Clontech, pSilencer 1.0-U6 siRNA 
Expression vector was purchased from Ambion. 
H2O2 (Hydrogenperoxide) was purchased from Fluka as a 10,2 M stock solution and 
stored at 4 °C in the dark. 
Agarose, molecular biology grade was from SIGMA. 
The following transfection reagents were used: 
 ExGen500 (Fermentas) 
 Jet PEITM (Qbiogene) 
 LipofectaminTM (Invitrogen) 
 Polyfect® (QIAGEN) 
 Transferrinfection (Alexis) 
 Metafectene (Biontex) 
 
2.3 Kits 
The following kits were purchased from QUIAGEN: 
QIAquick Gel Extraction Kit 
QIAprep Spin Miniprep Kit 
QIAGEN EndoFreeTM Plasmid Purification Kit 
The SilencerTM siRNA Construction Kit was from Ambion. 
The SuperSignal®West Femto Maximum Sensitivity Substrate kit was obtained from 
PIERCE. 
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2.4 Antibodies 
2.4.1 Primary antibodies 
Monoclonal anti-PARP-1 antibody (C2-10) was purchased from Alexis 
Biochemicals, CA, USA and was used at 1: 5000 dilution. 
Monoclonal anti-GAPDH antibody was obtained from Ambion, Texas, USA. The 
working dilution was 1:40000. 
Anti-green fluorescent protein antibody (anti-GFP) (rabbit IgG fraction) was obtained 
from Molecular Probes (2 mg/ml). Working dilution was 1:200. 
 
2.4.2 Secondary antibodies 
Goat anti-mouse (Fab specific) and goat anti-rabbit (whole molecule) 
antibodies were purchased from Sigma, Saint Louis, Missouri, USA. Both antibodies 
were peroxidase-conjugated and were used for development with the enhanced 
chemiluminescence (ECL) technique. 
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3. METHODS 
 
3.1 Cell culture 
Mouse embryonic fibroblasts (MEFs) were derived from PARP-1+/+ and 
PARP-1-/- mice and established in culture according to 3T3 protocol (Wang et al. 
1995). 
Cells were cultured at 37 °C in saturated humid atmosphere under 5 % CO2 in 
Dulbecco`s Modified Eagle`s Medium (DMEM) containing 4500 mg/l glucose, 
supplemented with 10% fetal bovine serum, 100000 units/l penicillin and 100 mg/l 
streptomycin (complete DMEM). 
Cell stocks were stored frozen in liquid nitrogen. To start the cultures, cells 
were thawed at 37°C, transferred into sterile tubes, diluted with cold complete 
medium and collected by centrifugation (5 minutes, 1000 rpm, 4°C; Eppendorf 
centrifuge 5810 R, Hamburg, Germany). Then cells were resuspended into 
prewarmed complete medium and transferred into 75 cm2 flasks. Medium was 
changed after 6-12 hours. 
Subculturing was done when the cultures reached confluence (every second 
to third day), at a split ratio 1:10. The cells were washed twice with prewarmed sterile 
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4), 
trypsinized (0.5 % Trypsin in PBS), collected in 15 ml cold medium and centrifuged at 
1000 rpm at 4°C for 5 min in an Eppendorf centrifuge 5810 R, Hamburg, Germany. 
Cells were resuspended in warm complete DMEM and transferred to the appropriate 
culture vessels. The medium was changed after 12 hours.  
 
3.2 Cell Treatments 
3.2.1 Transfection of pSilencerTM1.0-U6  
The expression vector pSilencerTM1.0-U6 (pSU6) was purchased from Ambion 
and modified to contain specific insert sequences as reported in “Results”. 
Transfection was done by either chemical or physical (electroporation) methods. 
In separate experiments, chemical transfection was achieved by the use of the 
following reagents: LipofectaminTM (Invitrogen), Polyfect® (QIAGEN), Metafectene 
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(Biontex), Ex Gen 500 (Fermentas), Jet PEITM (Qbiogene), and Transferrinfection 
(Alexis). 
All transfections were performed in the conditions recommended by the 
manufacturers including optimization of vector : transfection reagent ratios. 
Alternatively, cells were collected by trypsinization into Falcon Tubes and 
resuspended in incomplete DMEM at 4 x 106 cells/ml. Four hundred µl of suspension 
were transferred into each electroporation cuvette (BioRad) and pSU6 expression 
vector (1-5 µg/µl) was added to cells. The suspension was mixed by flicking the 
bottom of the cuvette.  Electroporation was performed using the BioRad 
electroporator GENE PULSER II at 950 µF capacitance and 0.25 kV. After 
electroporation the cells were seeded in 2 ml complete DMEM in 6 well plates. 
 
3.2.2 siRNA transfection 
Specific small interfering RNAs (siRNAs) were synthesized in vitro as 
described in section 2.9.  
Prior to transfection, 2 x 104 cells were seeded in 24 well plates until they 
reached 50 % confluence (about 24 hours). siPORT Amine (Ambion) was used as 
transfection reagent in conditions recommended by the manufacturer. Briefly, 
siPORT Amine was mixed (1:12; v:v) with OPTI-MEM I medium and incubated for 10-
30 minutes at room temperature. siRNA (20 µM) was added to diluted siPORT Amine 
transfection agent to a final concentration of 0.4 µM. The solution was mixed gently 
by pipetting and incubated at room temperature for 15-20 minutes. Fifty µl of this 
mixture (transfection agent/siRNA complex) were added dropwise to the 24 well plate 
containing 200 µl OPTI-MEM I/well and the dish was rocked to distribute the solution. 
The final concentration of siRNA in the plate wells was 80 nM. Cells were transferred 
to the incubator, and after 4-8 hours 1 ml of prewarmed complete DMEM was added 
to each well, to maximize cell growth and prevent potential cytotoxicity. 
  
3.2.3 Induction of DNA damage 
Oxidative DNA damage was induced by treatment with 100 µM H2O2 in 
incomplete medium at 37 °C. At the end of the treatment period, pictures were taken 
by a CCD Color Camera (KAPPA) connected to an Inverted Microscope DIAPHOT-
TMD (Nikon) and a Trinitron Color Video Monitor (Sony). 
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3.3 Preparation of whole cell lysates 
Cells in 24 well culture plates were placed on ice and washed twice with ice 
cold PBS. 200 µl of SDS sample buffer (Laemmli 1970) were added to each well and 
cells were scraped with a rubber policeman and collected into sterile Eppendorf 
tubes. Lysed cells were sonicated (5 cycles, 5 seconds, 37 % power; Bandelin 
Sonopuls, Berlin, Germany) and after heating at 95 °C for 2 minutes, insoluble 
material was discarded by centrifugation at 10000 rpm for 10 minutes (microfuge 
5415 R, Eppendorf, Hamburg, Germany). Supernatants were stored at –80°C until 
use. 
 
3.4 Protein quantification 
Protein concentrations were determined by the method of Lowry et al. (1951). 
Briefly, tubes containing either increasing amounts of BSA (from 1 mg/ml stock 
solution) or samples in lysis extraction buffer were prepared in duplicates. One ml of 
reaction mix (0.01% CuSO4 (w/v), 0.02% sodium potassium tartrate (C4H4NaKO6 • 
4H2O, w/v), 0.2 M NaOH and 4% Na2CO3) was added and the tubes were incubated 
for 10 minutes at room temperature.  After incubation, 100 µl of 50% (v/v) Folin and 
Ciocalteu`s phenol reagent were added. The tubes were immediately vortexed and 
incubated for another 10 minutes. Finally, absorbance at 750 nm was determined on 
an Ultraspec Plus spectrophotometer (Amersham Pharmacia Biotech, Little Chalfont, 
Buckinghamshire, UK). Protein concentration was calculated by extrapolation on a 
standard curve plotted with data relative to BSA. 
 
3.5 Electrophoretic analyses 
3.5.1 Agarose gel electrophoresis 
Electrophoresis was performed on 1 % agarose gels containing 0.5 µg/ml 
ethidium bromide. The gels were run horizontally in 1 x TBE buffer (89 mM TRIS, 89 
mM boric acid, 2 mM EDTA, pH 8.0) at 80 V for 1.5 hours. Results were visualized 
under UV light. 
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3.5.2 SDS-PAGE 
Proteins were separated on polyacylamide gels by standard SDS-PAGE 
technique (Laemmli 1970), using a Bio-Rad vertical electrophoresis unit. Ten % 
polyacrylamide gels were prepared, from a stock solution containing 29.2% (w/v) 
acrylamide and 0.8% (w/v) N,N-methylen-bisacrylamide. 
Electrophoresis was carried out at 125 V for 90 minutes in 25 mM Tris, 125 mM 
glycin, pH 8.3, containing 0.1% (w/v) SDS. 
 
3.6 Western blot analysis 
Following separation by SDS-PAGE, proteins were transferred onto 
polyvinylidene difluoride (PVDF) membranes (0.2 µm pore size, Bio-Rad, Hercules, 
CA, USA) using the Bio-Rad tank transfer system. The PVDF membranes were pre-
soaked in methanol and equilibrated in transfer buffer (12 mM TRIS, 96 mM Glycine, 
20% (v/v) Methanol). Transfer was accomplished at 125 V for 1.5 hours at room 
temperature. After transfer, the membrane was washed 3 times with TBST (10 mM 
Tris, 150 mM NaCl, 0.05% (v/v) Tween 20, pH 7.4). To block unspecific binding sites, 
membranes were incubated for 18 hours at 4 °C in TBST containing 5% (w/v) non-fat 
dry milk (TBSTM). Primary antibodies were diluted to desired concentrations (see 
section: 3.4 Antibodies) in 2.5% TBSTM and incubation was carried out in glass 
tanks for 60 minutes, at room temperature, on an orbital shaker.  
The membranes were subsequently washed 3 times for 10 minutes in 2.5% 
TBSTM, and then incubated for 60 minutes with appropriate peroxidase conjugated 
secondary antibodies diluted 1:10000 (anti-mouse IgG) or 1:15000 (anti-rabbit IgG), 
in 2.5% TBSTM. Finally the membranes were rinsed twice in 2.5% TBSTM and twice 
in TBST. 
Blots were developed by the technique of enhanced chemiluminescence 
(SuperSignal®West Femto Maximum Sensitivity Substrate kit from PIERCE). 
Immunodetected bands were quantified on a Computing Densitometer 325 
(Molecular Dynamics, now part of Amersham Pharmacia Biotech, Little Chalfont, 
Buckinghamshire, UK) using ImageQuant 3.3 (Molecular Dynamics) running on 
Windows 3.1 (Microsoft, Redmond, WA, USA). Data were normalized to GAPDH 
content in all analyses and expressed as ratio to the corresponding values in control 
cells.  
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3.7 Staining of protein blots 
Protein blotted on PVDF membranes were stained with Coomassie Blue. The 
membranes were equilibrated 2 minutes in 50% methanol/10% (v/v) acetic acid 
solution and then incubated with Coomassie staining solution (0.1% (w/v) Coomassie 
Blue R in 45% methanol/10% (v/v) acetic acid) for 1 minute with gentle agitation. 
After washing with 50% methanol/10% (v/v) acetic acid solution and incubation in 
H2O for 10 minutes, the membranes were finally air-dried and stored in plastic foil. 
 
3.8 Indirect immunofluorescence 
Cells grown on coverslips were rinsed twice in PBS and then fixed at -20 °C in 
ice-cold acetone methanol (1:1 (v/v)) for 20 minutes. After rehydration in PBS, cells 
were incubated for 1 hour in blocking solution (10 % (v/v) FBS, 0.01 % (v/v) Triton X-
100 in PBS, PBS-ST), followed by incubation with primary antibodies in PBS-ST, with 
gentle agitation. After 1 hour, coverslips were rinsed 3 times with PBS, and incubated 
for additional 1 hour with secondary antibodies conjugated with fluorescent marker 
(dilution 1:100). After 3 PBS washes, coverslips were incubated for 1 minute in DAPI 
(4',6-Diamidino-2-phenylindole) (10 µg/ml) and finally washed 3 times in PBS. 
Coverslips were air-dried, mounted on ethanol cleaned slides with Mowiol 
(Calbiochem, San Diego, USA) and analyzed under fluorescence microscope. 
 
3.9 RNAi constructs 
3.9.1 siRNA Oligonucleotide templates design  
In principle the selection of potential target sequences follows few rules that 
are applicable to both oligonucleotide templates for siRNA transcription in vitro and to 
insert sequences for an expression vector. 
Target sequences for siRNA were identified by first scanning target genes for 
AA sequences. The AA and downstream 19 nucleotides were recorded and 
compared to the mouse genome database to eliminate any sequences with 
significant homology to other genes. Oligonucleotides were designed to contain the 
selected gene-specific sequences in addition to sequences required for either in vitro 
transcription or cloning into expression vectors (see “Results”, paragraphs 4.1 and 
4.2) and were purchased from Microsynth, Balgach, Schweiz. A pending patent 
application precludes sequence specifications of the siRNAs used in these studies. 
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3.9.2 Construction of siRNA expression vector 
 
siRNA Insert Preparation  
Forward and reverse oligonucleotides for the siRNA insert were dissolved in 
10 mM TRIS-HCl (pH 8.0) to a final concentration of 1 µg/µl. Oligonucleotides were 
annealed in HEPES-buffer (30 mM HEPES-KOH, pH 7.4; 100 mM K-acetate; 2 mM 
Mg-acetate) by heating to 90 °C for 3 minutes followed by incubation at 37 °C for 
1 hour.  
 
Cloning of the siRNA sequences into pSilencerTM 1.0-U6  
The pSilencerTM1.0-U6 Vector was digested with Eco R I and Apa I restriction 
enzymes (BioLabs, New England) in succession. In a 50 µl reaction mixture 10 µg of 
pSU6 were incubated with NEBuffer Eco R I (50 mM NaCl; 100 mM Tris-HCl; 10 mM 
MgCl2; 0.025 % Triton X-100 (pH 7.5)) and 20 units Eco R I at 37 °C for 1 hour. The 
reaction was stopped by heat inactivation of the enzyme at 65 °C for 20 minutes and 
the digested plasmid was analyzed by 1% agarose gel electrophoresis. Linearized 
vector was purified by extraction from agarose gel (QIAquick Gel Extraction Kit). 
The linearized vector was incubated in NEBuffer 4 (50 mM potassium acetate; 
20 mM Tris-acetate; 10 mM magnesium acetate; 1 mM dithiothreitol (pH 7.9)), 
containing 0.1 mg/ml BSA and 20 units Apa I at 25 °C for 1 hour, in 50 µl final 
volume. Reaction was stopped by heat inactivation of the enzyme at 65 °C for 20 
minutes followed by analysis on 1 % agarose gel of the product. Linearized vector 
was extracted from agarose gel, and purified as described above. The purified linear 
plasmid was quantified by measuring the absorbance at 260 nm by an Ultraspec Plus 
spectrophotometer (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, 
UK) and diluted to a final concentration of 0.5 µg/µl.  
Finally, 500 ng Eco R I/Apa I linearized expression vector were mixed with 
16 ng double-stranded siRNA insert and incubated with 1 unit T4 DNA Ligase in the 
appropriate buffer (Ambion), at room temperature, overnight. 
 
Amplification of pSilencerTM 1.0-U6 siRNA Expression Vector and selection of 
positive clones 
Five µl of ligation reaction mixture or 10 ng of pSU6 empty vector were used to 
transform competent E.coli DH5α cells (100 µl) by heat shock. Transformants were 
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plated onto Luria-Bertani Medium (LB) agar plates containing 100 mg/l ampicillin. 
After 16 hours, single colonies were inoculated in LB medium containing 100 mg/l 
ampicillin and grown at 37 °C for 24 hours. Plasmids were isolated by spin column 
chromatography using the QIAprep Spin Miniprep Kit. Plasmid concentration was 
determined by measuring the absorbance at 260 nm. Purified plasmids (2 µg) were 
digested with 20 units Hind III (BioLabs, New England) in NEBuffer 2 (50 mM NaCl, 
10 mM TRIS-HCl, 10 mM MgCl2, 1 mM dithiothreitol, (pH 7.9)) in a 50 µl reaction 
mixture, at 37 °C for 1 hour to identify the plasmids containing the siRNA inserts, 
digestion products were analyzed by 1% agarose gel. Positive plasmids were 
amplified in competent DH5α cells, as described before, and purified using the 
QIAGEN EndoFreeTM Plasmid Purification Kit. Aliquots of transformed bacteria were 
frozen as glycerol stock solutions at -80 °C. 
 
3.9.3 siRNA synthesis by in vitro transcription 
siRNAs were synthesized using the SilencerTM siRNA Construction Kit 
(Ambion). In separate reactions, dry supplied sense and antisense 29-mer DNA 
oligonucleotide templates with 21 nt encoding the siRNA and 8 nt complementary to 
the T7 Promoter Primer were dissolved in nuclease-free TE-Buffer (10 mM Tris-HCl 
pH 8.0, 1 mM EDTA), to have a final concentration of 100 µM. Each DNA 
oligonucleotide template was hybridized to the T7 promoter primer in “DNA Hyb 
Buffer” provided with the kit, by heating to 70 °C for 5 minutes followed by 5 minutes 
cooling at room temperature. The 3’ ends of the hybridized oligonucleotides were 
extended using a DNA polymerizing reaction, as described in the kit protocol. The 
resulting ds oligonucleotide templates were used in an in vitro transcription reaction 
to synthesize sense and antisense siRNAs. The two RNA products were hybridized 
by combining by overnight incubation at 37 °C. To remove 5’ overhanging leader 
sequences and to eliminate DNA templates, the dsRNA hybridization mixture was 
subjected to digestion with single-strand specific RNase and DNase by incubation at 
37 °C for 2 hours in the appropriate buffer. 
siRNA was separated from nucleotides, enzymes, short oligomers and salts 
present in the reaction mixture by column chromatography (SilencerTM siRNA 
Construction Kit, Ambion). siRNA was eluted from column into 100 µl of nuclease-
free water; the concentration was measured by reading the absorbance at 260 nm 
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and adjusted to 20 µM. The quality of siRNAs was analysed by 1% agarose gel 
electroporesis. 
An outline of siRNA synthesis procedure is given in Fig. 4. 
 
 
 
Figure 4: Silencer siRNA Construction (Ambion) 
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4. RESULTS 
 
4.1 RNAi by the siRNA expression vector pSilencerTM 1.0-U6   
The pSilencer 1.0-U6 (pSU6) siRNA Expression Vector has been designed for 
plasmid-based siRNA experiments. It is a 3.3 Kb vector, containing sequence 
elements for cloning and bacterial replication, i.e. f1 origin, CoIE1 origin, Ampicillin 
resistance gene, and multiple cloning site (Fig. 5). A U6 RNA Polymerase III (Pol III) 
promoter (-315 to +1) is cloned into the Kpn I and Apa I sites to generate small RNA 
transcripts. The U6 Pol III promoter was chosen because Pol III has well-defined 
initiation and stop sites from its promoter to a string of 4-5 uridines.  
 
   
Figure 5: pSilencerTM1.0-U6 siRNA Expression Vector (Ambion)  
 
 
In general, after selection of 19-nucleotide siRNA sequences, downstream of 
AA dinucleotides (see Methods 2.9.1) on the mRNA of the gene of interest, two DNA 
oligonucleotides, ∼55 nt in size, are designed as insert sequences (Fig. 6). 
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Figure 6: Schematic representation of a siRNA insert 
 
In the forward oligonucleotide, the 19-nucleotide sense siRNA sequence is 
linked to the reverse complementary antisense siRNA sequence by a 9-nucleotide 
spacer (TTCAAGAGA). 5-6 Ts are added to the 3’ end of the oligonucleotides. In the 
reverse oligonucleotide, 4-nucleotide overhangs to the EcoR I (AATT) and Apa I 
(GGCC) restriction sites are added to the 5’ and 3’ end of the 54 nt sequence 
complementary to the forward oligonucleotide, respectively. The resulting RNA 
transcript is likely to fold back and form a stem-loop structure comprising 19 bp stem 
and 9 nt loop with 2-3 Us at the 3’ end (Fig. 7). 
 
 
  
 
 
   
 
Figure 7: Haipin structure of the RNA transcript 
 
 
4.1.1 Insertion of siRNA sequences into pSU6 
The pSU6 expression vector was first linearized with the restriction enzyme 
Apa I as described under “Materials and Methods”. The completion of the digestion 
reaction was controlled by agarose gel electrophoresis. As shown in Fig. 8 A, the fast 
migrating band, corresponding to supercoiled pSU6 (lane 1), was converted to the 
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slower migrating linear form (lane 2), at the end of the incubation time. In a second 
step, the linearized vector was digested with Eco R I and purified. The final digestion 
product migrated as a single band on agarose gel (Fig. 8 B).  
 
  
Figure 8: Digestion of pSU6 expression vector 
pSU6 was linearized with Apa I (A) and subsequently digested with Eco R I (B). 
Analysis was by 1% agarose gel electrophoresis. 
 
 
Three different potential siRNA sequences (A, B and C) targeting sites within 
the DNA binding domain of mouse PARP-1 were selected and the corresponding 
oligonucleotides were inserted into Apa I/Eco RI digested pSU6, as described under 
“Materials and Methods”. One sequence complementary to a site within GAPDH 
mRNA was used as a positive functional silencing control. GAPDH protein is 
expressed in most mammalian cells at levels that can be readily detected by western 
blot analyses.  
To select positive clones that contain siRNA inserts, plasmids purified from 
different clones were digested with Hind III restriction enzyme: plasmids with the 
insert are not digested by Hind III, as the restriction site has been removed by the 
double Apa I/Eco R I digestion (see Fig. 5); on the contrary the original pSU6 is 
linearized by this treatment.  
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Figure 9: Selection of positive clones by restriction analysis. 
Agarose gel electrophoresis of pSU6 (co), clones 1-7 of the three pSU6-PARP-1 
constructs (A, B, C) and clones 1-5 of pSU6-GAPDH. For each pair of samples, the 
first lane corresponds to the undigested plasmid and the second one to the Hind III 
digested plasmid, lane 7 only digested plasmids are shown. 
 
 
As shown in Fig. 9 clones No 1, 3, 4 and 5 of pSU6-PARP-1-A, all 7 clones of 
pSU6-PARP-1-B, clone No 2 – 7 of pSU6-PARP-1-C and clone No 1, 2 and 3 of 
pSU6-GAPDH were not digested by Hind III. Plasmids from these clones were 
amplified, purified and used in most of the following experiments. 
 
4.1.2 Chemical transfection 
In the last years many different chemical transfection reagents have been 
developed. In this study, I tested six different reagents for transfection of pSU6 
silencing constructs in mouse embryonic fibroblasts. Three of them were based on 
Polyethylenimine (ExGen 500, JetPEI and the Transferrinfection method), one was 
based on liposome formulation (Lipofectamin), one on dendritic molecules (Polyfect 
Transfection Reagent) and one on repulsive membrane acidolysis technology 
(Metafectene Transfection Reagent). All reagents were used as recommended by the 
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manufacturers. To ensure high transfection efficiency, for all transfection reagents 
optimization was performed by varying the transfectant/DNA ratio. 
Cells were transfected with either pSU6-GAPDH or pSU6-PARP-1 A, B or C. 
After 24 hours, whole cell lysates were prepared and analyzed by western blot; 
immunodetected bands were quantified by scanning densitometry. Equal loading was 
confirmed by immunodetection of either Tubulin (for pSU6-GAPDH transfected cells) 
or GAPDH (for pSU6-PARP-1 transfected cells).  
As shown in Fig. 10, using six different chemical transfection reagents neither 
GAPDH nor PARP-1 expression could be downregulated to a significant extent: the  
maximum reduction of the targeted proteins was 10% of basal levels.  
 
 
Figure 10: Effects of pSU6-GAPDH and pSU6-PARP-1-A chemical transfection 
in MEFs. Western blot analyses of whole cell lysates, antibodies against Tubulin, 
GAPDH and PARP-1 were used. (A)-(E): cells were either mock transfected (-) or 
transfected with pSU6-GAPDH (+); (F): cells were transfected with either pSU6-
GAPDH (left panel) or pSU6-PARP-1-A (right panel) at different lipid:DNA ratios 
(lanes 1-3) and mock transfected cells (lane 4). 
 
There are different possible reasons why protein silencing was unsuccessful in 
these experiments. First of all, efficient DNA transfection is a critical parameter. Thus, 
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one possibility could be that the uptake of vector DNA by the cells was very low. 
Another possibility is that the Polymerase III promoter is less active than expected. 
The third alternative is that the tested sequences are not good candidates for gene 
silencing by RNAi. However, this last possibility applies only for PARP-1 sequences, 
as the silencing potential of the GAPDH sequence was proven before by many 
research groups.  
To determine whether the negative silencing results were due to low uptake of 
plasmid DNA by MEFs under the culture conditions used, a plasmid, 5.9 kbp in size, 
coding for GFP-p53 fusion protein, under the CMV immediate-early promoter, was 
chemically transfected. The GFP-p53 plasmid uptake was analyzed by indirect 
immunofluorescence of the expressed protein using anti-GFP antibodies. By 
transfecting the cells with ExGen 500 less than 5 % of cells took up the GFP-p53 
plasmid, as indicated by the low number of stained nuclei (Fig. 11). All other tested 
reagents showed comparable low transfection efficiencies (data not shown). 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Indirect immunofluorescence of GFP-p53 in MEFs using anti-GFP 
antibodies (400 x magnification). Cells were transfected using the chemical 
transfection reagent ExGen 500. Left: DAPI staining of DNA; right: immunostaining 
with polyclonal antibody against GFP and FITC-conjugated anti-rabbit IgG. No 
background fluorescence was detectable in mock transfected cells. 
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4.1.3 Transfection of pSU6 by electroporation 
Electroporation is a physical transfection method that involves the exposure of 
cells to a pulsed electric field which presumably creates pores in the plasma 
membrane. It has been used to introduce DNA into animal cells and has been 
successfully applied to a wide range of cell types which had not been accessible to 
other methods. Electroporation could therefore be the method of choice for efficient 
transfection of pSU6 in MEFs. To investigate the uptake of plasmid DNA by 
electroporation, the GFP-p53 plasmid was used and the expression of GFP-p53 was 
analyzed by indirect immunofluorescence using antibodies against GFP. As shown in 
Fig. 12 about 40 % of cells showed a nuclear staining, indicating uptake of plasmid 
and GFP-p53 expression. 
 
 
 
Figure 12: Indirect immunofluorescence of GFP-p53 transfected MEFs using 
anti GFP antibodies. Cells were transfected by electroporation. Left: 400 x 
magnification, right: 1000 x magnification (oil immersion). Blue: DAPI staining of 
DNA, yellow: indirect immunostaining of GFP-p53 by polyclonal anti-GFP antibody 
and FITC-conjugated anti-rabbit IgG.  
  
 
In a next step, the suitability of electroporation to deliver siRNA-expression 
vectors was tested with the pSU6-GAPDH construct. As it is reported that addition of 
carrier DNA may increase transfection efficiencies, the vector was transfected either 
alone or in combination with salmon sperm (ss) DNA (0.23 µg/µl). In addition, a 
special plasmid purification kit was used to ensure endotoxin-free plasmid 
preparations. After 24 hours, whole cell lysates were analyzed by western blot and 
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scanning densitometry for quantification of GAPDH. GAPDH content was normalized 
to PARP-1 and the data were expressed as percent of the corresponding values for 
control cells (mock transfected cells). Results are shown in Fig. 13.  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: GAPDH levels in MEF`s transfected with pSU6-GAPDH by 
electroporation. (A): Western blot analysis of whole cell lysates. Lane 1: control 
cells, lane 2: pSU6-GAPDH (endotoxin-free), lane 3: pSU6-GAPDH + salmon sperm 
DNA, lane 4: pSU6-GAPDH. (B): quantification of the blot shown in A. 
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GAPDH protein levels were reduced by 40 % - 50 % in electroporated cells. 
The endotoxin-free plasmid gave slightly better results than the plasmid purified 
under standard conditions (45 % GAPDH reduction compared to 40 %). Also, a slight 
improvement was obtained by cotransfection of pSU6-GAPDH with carrier DNA.  
 
 
4.2 Downregulation of PARP-1 expression using siRNAs 
In this work, six different siRNAs with sequences matching distinct 21-nt 
coding regions within the DNA binding domain of PARP-1 (sequences A-F) were 
produced by in vitro transcription and purified as described under “Materials and 
Methods”. A GAPDH siRNA and scrambled PARP-1 sequence E were used as 
positive and negative controls, respectively. The quality of siRNAs at intermediate 
and final steps of the purification procedure was assessed by agarose gel 
electrophoresis. As an example, Fig. 14 shows the siRNA corresponding to PARP-1 
sequence A, before and after a final digestion with single-strand specific ribonuclease 
to eliminate 5`-overhang sequences (see Methods, 2.9.3 for details). 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Agarose gel electrophoresis analysis of siRNA 
siRNA before (lane 1) and after (lane 2) enzymatic digestion and purification. 
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The siRNA amount used for transfection is critical to the success of gene 
silencing experiments. Transfecting too much siRNA causes nonspecific reductions 
in gene expression and toxicity to the transfected cells. Transfecting too little siRNA 
does not change the expression of the target gene.  The concentration of the siRNA 
preparations was determined on the basis of the absorbance at 260 nm and further 
confirmed by agarose gel electrophoretic analysis (Fig. 15). With the only exception 
of siRNA PARP-1 sequence A (lane 1), all other siRNAs had similar concentrations 
(lanes 2-7)  
 
 
  
Figure 15: Electrophoretic analysis of in vitro transcribed and purified siRNAs 
 
.2.1 Silencing efficiency of different siRNAs  
In vitro transcribed siRNAs were transfected into MEFs and the levels of 
PARP
2.8 µg of PARP-1 siRNAs (A-F; lane 1-6) and GAPDH-siRNA (lane 7) were analyzed
on 1.5 % agarose gel.  
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-1 and GAPDH protein were analyzed by Western blot and scanning 
densitometry 24 hours after transfection, numbers otherwise specified. An example of 
Western blot analysis is given in Fig. 16. Controls included cells that were either 
mock transfected or transfected with siRNA containing the same nucleotides as 
sequence PARP-1 E but in a randomly mixed order (PARP-1 E scrambled).  
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Figure 16: Western blot analysis of PARP-1 silencing in MEFs. 
Whole cell lysates from mock transfected cells (lane 2) and cells transfected with 
PARP-1 sequence F (lane 1), PARP-1 sequence E (lane 3) and PARP-1 sequence E 
scrambled (scr.; lane 4). 
 
 
Relative to mock transfection and PARP-1 E scrambled siRNA, all six PARP-1 
siRNAs reduced PARP-1 protein content, albeit to a different extent (Fig. 17). PARP-
1 C- and E-siRNAs appeared to be the most effective. In particular PARP-1 E siRNA 
reduced PARP-1 expression to nearly undetectable levels, whereas PARP-1 C 
siRNA reduced protein levels by about 65 %. PARP-1 siRNAs A, B, D and F induced 
a reduction of PARP-1 expression by 30 to 40 %. The positive control GAPDH siRNA 
reduced GAPDH expression by about 60 %. For any given sequence, variations in 
the level of silencing in different experiments may be due to different transfection 
efficiencies. 
Taken together, this series of experiments demonstrate that PARP-1 E-siRNA 
is the best candidate for PARP-1 silencing.  
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Figure 17: Silencing of PARP-1 and GAPDH by siRNA transfection 
PARP-1 and GAPDH were detected by Western blot and quantified by scanning 
densitometry. PARP-1 content was normalized to GAPDH, while for GAPDH silenced 
cells, PARP-1 was used for normalization. Normalized data are expressed as % of 
the corresponding values for control (mock transfected) cells +/- SD. 
 
 
 
4.2.2 siRNA dose-dependent silencing of PARP-1 
When MEFs were transfected with PARP-1 E-siRNA at different 
concentrations (40 µM, 80 µM and 200 µM), similar reduction of PARP-1 levels was 
observed (Fig. 18, compare lanes 1, 2 and 3). Therefore 40-80 µM siRNA 
concentrations were chosen for further experiments. Compared to mock transfected 
control cells, the inhibition of PARP-1 expression by PARP-1 E-siRNA was calculated 
to be higher than 60% (Fig. 18, compare lane 1, 2 and 3 with lane 4). The lack of 
complete inhibition may be the consequence of low transfection efficiency in this 
experiment.  
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Figure 18: PARP-1 silencing by different amounts of siRNA   
Whole cell lysates from MEFs transfected with increasing amounts of PARP-1 E 
siRNA were analyzed by Western blot using anti-PARP-1 or anti-GAPDH antibodies. 
 
 
 
4.2.3 Effect on PARP-1 expression of combined siRNAs  
The use of a single species of siRNA to target mRNA is not a biologically 
relevant situation, as cells would normally encounter multiple siRNAs produced from 
long dsRNA by the RNase III-like DICER. I asked whether the complexes involved in 
cleaving the mRNA might have evolved to utilize multiple siRNA species, for instance 
through a mechanism of allosteric stimulation of RISC, and thus work more efficiently 
with multiple siRNAs. Specifically, I wanted to know whether combinations of siRNAs 
would result in increased activity through synergism or addition. Testing this concept 
by co-transfecting various combinations of two siRNAs in MEFs, no additive or 
synergistic effect could be discerned by western blot analyses (Fig. 19). Co-
transfection of two semipotent sequences (PARP-1 D and F) together did not cause 
any further silencing then each of them separately (compare lane 2 with lanes 3 and 
4). Co-transfecting one active (E-siRNA) and one less-active C-siRNA did not reduce 
the silencing potential of the very potent E-siRNA (compare lane 5 with lanes 6 
and 7).  
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 Figure 19: Downregulation of PARP-1 expression using combined siRNAs. (A): 
Western blot analysis of PARP-1 and GAPDH in whole cell lysates from control 
(mock transfected) cells (lane 1 and 8) and cells either transfected with one PARP-1 
siRNA alone (lane 3, 4, 6 and 7), or transfected with combinations of PARP-1 siRNAs 
(lane 2 and 5). (B): Quantification of the Western blot shown in A. 
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4.2.4 Time course of PARP-1 silencing by siRNAs 
A crucial aspect of RNAi experiments is the time required to reduce protein 
expression below the threshold level that is critical to sustain normal protein function. 
As shown in Fig. 20, PARP-1 content in MEFs was reduced to undetectable levels 
already 24 hours after PARP-1 E-siRNA transfection.  
On the other hand, the approach of gene silencing by direct transfection of 
siRNAs into mammalian cells is limited by the transient nature of the silencing effect 
as the siRNAs are turned over by the cell. Western blot analysis of MEFs harvested 
24, 48 and 72 hours after transfection with PARP-1 E-siRNA showed that the 
silencing effect lasts at least up to 72 hours (Fig. 20). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Time course of PARP-1 silencing (A): Western blot analysis of whole 
cell lysates from control (mock transfected) cells (lane 4) and PARP-1 E-siRNA 
transfected cells harvested 24, 48 and 72 hours after transfection (lane 1-3). (B): 
Quantification of the Western blot shown in A.   
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4.2.5 Response to oxidative stress of PARP-1 wild-type and PARP-1-deficient 
cells 
MEFs were treated with 200 µM H2O2 as described in “Materials and Methods” 
and observed under a phase contrast microscope. This treatment had different 
effects, depending on the PARP-1 status of the cells. 
As shown in Fig. 21, PARP-1 wild type cells appeared to be very sensitive to 
oxidative stress and after 30 minutes of incubation at 37 °C in the presence of H2O2 
most of them detached from the plate while the remaining cells exhibited a rounded 
shape. In contrast, PARP-1 silenced cells (E-siRNA, 24 hours after transfection) as 
well as PARP-1 knock-out cells resisted this treatment; thus confirming PARP-1 
involvement in oxidative stress induced cytotoxicity.  
 
 
 
Figure 21: Effect of H2O2 in the presence and absence of PARP-1. Phase 
contrast microscopy (20 x objective). 
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5. DISCUSSION 
  
5.1 Comparison of strategies to induce RNAi 
Over the last couple of years a large variety of techniques have emerged that 
make dsRNA-induced silencing applicable to mammalian cells. Each is associated 
with specific advantages and disadvantages (Table 1). 
 
 
 
TABLE 1 
 
Advantages and Disadvantages of Different siRNA Delivery Strategies 
___________________________________________________________________ 
 
     Advantages   Disadvantages 
___________________________________________________________________ 
 
Chemical and in vitro 
enzymatic synthesis  Rapid synthesis   Transient RNAi 
RNAse III: produces siRNA mixtures,  Purity and specificity using  
  obviating need for testing the    enzymatic synthesis is  
  efficacy of siRNAs separately     variable 
High purity using chemical synthesis Chemical synthesis expensive  
  for multiple siRNAs 
Transfection-dependent 
 
DNA plasmid vector or 
Cassette   More economical for multiple  More labor intensive to 
      sequences      generate 
    Stable RNAi achievable using  Transfection-dependent 
      selection marker 
 
Virus-mediated   May be effective in cells  More labor intensive to  
      resistant to transfection with    generate 
      dsRNA and plasmids   Potential biohazard 
    Integration produces stable RNAi 
      even in the absence of a selection  
      pressure 
 
___________________________________________________________________ 
    
        (Duxbury et al. 2004) 
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In the work presented here, I set up conditions for PARP-1 gene silencing in 
MEFs using two different strategies: one approach involved the use of polymerase III 
promoter-based DNA plasmids which express siRNA within the cells, while the 
second was based on the direct transfection of in vitro transcribed siRNAs. 
 
The siRNA expression vector system 
Using this approach, siRNAs are produced by polymerase III promoter-based 
DNA plasmids or expression cassettes (Sui et al. 2002). These constructs produce 
small inverted repeats, separated by a spacer of three to nine nucleotides, termed 
short hairpin RNAs (shRNAs), which are processed by Dicer into siRNAs (Paddison 
et al. 2002). Transcription begins at a specific initiation sequence, determined by the 
promoter used. In addition to a defined initiation sequence, the U6 polymerase III 
promoter terminates at TTTT or TTTTT (Bogenhagen et al. 1980), giving as a product 
shRNAs that contain a series of uridines at the 3` end, a characteristic which appears 
to facilitate RNAi (Elbashir et al. 2001b). 
 
Although, the vector based system is more labor intensive to generate, it was 
chosen first because of the higher stability of DNA plasmid relative to RNA molecules 
and because RNAi can be sustained for as long as 2 months post-transfection 
(Brummelkamp et al. 2002a).  
While sufficient gene silencing using U6-expression vector systems has been 
achieved by many groups, in the experiments reported in this thesis, using different 
chemical transfection methods in mouse embryonic fibroblasts, the system has failed 
to give appreciable downregulation of PARP-1 as well as of GAPDH (Fig. 10).  
In general three reasons are conceivable regarding inefficient silencing: 1. Tested 
sequences ineffective to induce RNAi, 2. Low activity of the Polymerase III promoter; 
3. Low transfection efficiencies of expression vectors. 
The three different PARP-1 sequences (A, B and C) have been chosen 
randomly among potential target sequences in the region coding for the DNA binding 
domain of PARP-1. It was the aim of this work to set up conditions for effective RNAi 
of PARP-1, which includes the identification of suitable target sequences. Thus, it 
cannot be excluded that the tested sequences failed to reduce PARP-1 protein levels 
because they are simply not good candidates for RNAi. However, this was certainly 
not the case for the GAPDH-siRNA. In fact, the siRNA used with a sequence derived 
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from the 5`medial region of the GAPDH mRNA, has been shown to reduce the 
expression of GAPDH by 50-95 % in several mammalian cell lines (Brown et al. 
2002), and is generally used as a positive control in siRNA experiments. Using 
different chemical transfection reagents and the pSU6-GAPDH, I did not find any 
appreciable downregulation of GAPDH. Hence it must be assumed that either 
transfection was inefficient or that in mouse embryonic fibroblasts the polymerase III 
promoter is less active than expected. As the polymerase III promoter has been 
shown to successfully knock down the expression of cdk-2 and lamin A/C in diverse 
cell lines (Sui et al. 2002), low transfection efficiencies are the most probable reason 
for the observed absence of downregulation.   
This conclusion is supported by the results obtained in an independent series 
of experiments in which transfection efficiencies were evaluated by using a GFP-p53 
expression vector and indirect immunofluorescence with an anti-GFP antibody. 
Results showed that a maximum of 5 % of the cells took up the plasmid regardless of 
the transfection reagent used. Better transfection efficiencies could be obtained by 
electroporation, a method that involves the exposure of cells to a pulsed electric field 
under controlled conditions: in this case up to 40 % of the cells took up the plasmid 
and expressed GFP-p53 (Fig. 12). Accordingly, electroporation of pSU6-GAPDH 
resulted in about 50 % reduction of GAPDH (Fig. 13). The increase in the silencing 
effect using electroporation in comparison to chemical transfection is in line with 
reports that show that physical transfection methods can be successfully used to 
introduce DNA in cell types which have not been accessible to other transfection 
methods (Chu et al. 1987). 
  
Recently, expression vectors with antibiotic selectable markers have become 
available: in these cases transient antibiotic selection permits enrichment of the cells 
that have received the plasmid, thus compensating for low transfection efficiencies. 
These vectors may be used in the future in alternative to pSU6 for PARP silencing. 
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siRNAs 
In contrast to expression vectors, in vitro transcribed siRNA molecules can be 
easily transfected into mammalian cells. The strategy of in vitro enzymatic synthesis 
of siRNAs is becoming increasingly popular because this method is rapid and may be 
the best approach for initial “proof of principle” experiments as well as siRNAs 
synthesized by industrial chemical processes (Micura 2002).  
The method relies on the transcription of specific oligonucleotides by the T7 
phage polymerase (Donze and Picard 2002). The polymerase produces individual 
RNA molecules, sense and antisense strands, which, when annealed, form siRNAs. 
Extra nucleotides required by the T7 promoter are removed by RNase digestion and 
cleaning steps.  
 
In this thesis, six different siRNA with sequences matching the DNA binding 
domain of PARP-1 were synthesized and tested for their ability to downregulate 
PARP-1 expression. PARP-1 E-siRNA has proven to be the best candidate for gene 
silencing, as it reduced PARP-1 content to undetectable levels (Fig. 20). 
siRNAs targeting different positions on PARP-1 mRNA differed in their 
silencing potency, with reduction of PARP-1 ranging from 35 to 98 % of basal levels 
(Fig. 17). This feature can be exploited experimentally to modulate, rather than 
suppress, PARP-1 expression into the cells. 
An important point in experiments is the time required to reduce protein 
expression below the threshold level that is critical to sustain normal protein function. 
This is in large part determined by the efficiency of the siRNA to target the mRNA of 
choice. But in addition, protein stability is a critical factor. The time required to reduce 
protein expression below the critical level, once the mRNA is degraded or translation 
is shut off, is primarily determined by the half-life of that protein. PARP-1 is a protein 
with a relatively short half-life. In fact, with the most potent siRNA, the maximal effect 
was observed already after 24 hours.   
An important factor that has to be considered is the transient nature of the 
silencing effect obtainable by siRNA transfection. As the siRNAs are turned over by 
the cell, the silenced genes can recover in time, limiting this approach to analysis for 
short time periods (Duxbury et al. 2004).  
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Western blot analysis of MEFs harvested 24, 48 and 72 hours after the start of 
transfection with PARP-1 E siRNA showed that indeed the silencing effect lasts at 
least up to 72 hours (Fig. 20). 
 
5.2 PARP-1 knockdown and oxidative stress 
The PARP-1 suicide hypothesis suggests that massive DNA damage, which 
occurs with severe oxidative stress, may trigger the activation of PARP-1 to such an 
extent that all the cellular NAD+ may be depleted (Berger et al. 1983). Thus, the 
cellular energy supply may become deficient and this may lead to functional and 
morphological alterations which may result in cell death. Studies with PARP-1 
knockout mice as well as PARP inhibitors confirm the role of PARP-1 in oxidant-
mediated cell death (Chiarugi 2002).  
In fact, the absence of PARP-1 activity protects cells against the cytotoxic 
effects of oxidizing agents.  
To functionally validate PARP-1 silencing by RNAi, PARP-1 silenced cells 
were treated with H2O2 for 30 minutes and compared with wild-type and PARP-1 
knockout cells receiving the same treatment. PARP-1 silenced cells, as well as 
PARP-1 knockout cells, proved to be more resistant to oxidative stress (Fig. 21).  
 
In conclusion, having established conditions for effective PARP-1 silencing 
using the siRNA transfection method, these studies will provide an essential 
background for further investigations. In particular, the acquired know-how will 
facilitate the identification and production of siRNA targeting other components of the 
PARP family. An interesting candidate is obviously PARP-2, which shares with 
PARP-1 a “guardian of the genome” function, but is most probably involved also in 
other vital processes, as suggested by studies with knockout mice.  
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7. SUMMARY 
 
Poly(ADP-ribose) polymerases (PARPs) constitute a family of related proteins 
that play diverse roles in various cellular functions, and share a highly homologous 
catalytic domain with a common enzymatic activity: the synthesis of variously sized 
ADP-ribose polymers, covalently bound to acceptor proteins. In this reaction, the 
respiratory coenzyme nicotinamide adenine dinucleotide (NAD+) serves as a source 
of ADP-ribose moieties. 
This thesis work was aimed at setting up conditions for specific silencing of 
individual PARPs in living cells using RNA interference (RNAi). RNAi is a recently 
developed technique that has proven to be a powerful tool for rapid and specific 
downregulation of target genes. PARP-1, the most abundant and best characterized 
member of the PARP family, was chosen as an initial target. 
To knock-down PARP-1 in mouse embryonic fibroblasts (MEFs), two 
approaches out of the various techniques for RNAi were tested. One approach 
involved the use of polymerase III promoter-based DNA plasmids which express 
siRNA within the cells. Even though it is labor intensive, this system has the 
advantage of allowing RNAi over a long time period. A disadvantage is that the 
success of this strategy suffers from the low transfection efficiency of DNA plasmids. 
The second approach was based on the direct transfection of in vitro transcribed 
siRNAs; siRNA molecules can be easily transfected into mammalian cells but, on the 
other hand, RNAi can be obtained only transiently. 
In regard to the first approach, three sequences targeting different regions in 
the PARP-1 gene were inserted in the pSilencer 1.0-U6 vector (pSU6) and 
transfected into MEFs using different chemical transfection methods. A plasmid 
expressing siRNA targeting the glycolytic enzyme GAPDH was used as a positive 
control. As monitored by immunoblotting, the system failed to give appreciable 
downregulation of PARP-1, nor of GAPDH. On the basis of an independent series of 
experiments, in which a GFP-p53 expression vector was chemically transfected into 
MEFs, the failure of gene silencing could be attributed to low transfection efficiencies. 
Better transfection efficiencies could be obtained using electroporation, by which 
40 % of the cells took up the plasmid and expressed GFP-p53. Accordingly, 40-50 % 
reduction of GAPDH cellular content could be achieved by electroporation of the 
specific siRNA-pSU6 construct.  
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In regard to the second approach, six different siRNAs with sequences 
matching the DNA binding domain of PARP-1 were synthesized in vitro and tested for 
their ability to downregulate PARP-1 expression. Immunoblotting analyses revealed 
that siRNA molecules, targeting different positions on PARP-1 mRNA, were able to 
reduce PARP-1 expression from 35 % to more than 98 % of basal levels within 24 
hours and that the silencing effect persists at least up to 72 hours after transfection. 
As expected, and in agreement with data from mice knockouts, post-transcriptional 
silencing of PARP-1 by RNAi did not cause any obvious phenotype under normal 
growth conditions; however, silenced cells appeared to be more resistant against 
oxidative stress than wild-type cells. 
In conclusion, these studies establish conditions for effective PARP-1 silencing 
in cultured cells; this will provide an essential background for further investigations on 
the role of PARP-1 and, more generally, of poly (ADP-ribose) synthesis, in the 
response to DNA damage. The acquired know-how will facilitate the identification and 
production of siRNA targeting other components of the PARP family. 
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8. ZUSAMMENFASSUNG 
 
Die Familie der Poly(ADP)polymerasen (PARPs) bezeichnet verwandte 
Proteine, die unterschiedliche Rollen bei verschiedenen zellulären Funktionen 
spielen. Allen PARP Proteinen gemeinsam ist eine stark homologe Domäne mit 
enzymatischer Aktivität, die die Synthese von ADP-Ribose Polymeren verschiedener 
Größe katalysiert. Die Polymere werden kovalent an Akzeptorproteine gebunden, 
wobei in der Reaktion das respiratorische Koenzym Nikotinamid-Adenin-Dinukleotid 
(NAD+) als Substrat für die ADP-Ribose-Einheiten dient. 
Ziel der vorliegenden Arbeit war es, ein System zu entwickeln, dass die 
Downregulation von PARP-Proteinen mittels RNA Interferenz (RNAi) in Zellkulturen 
ermöglicht. RNAi ist eine vor kurzem entwickelte Technik, die zu einer schnellen und 
spezifischen Downregulation von Genen führt. Die notwendigen Bedingungen für ein 
effizientes Gen Silencing wurden zunächst für PARP-1, das am häufigsten 
vorkommende und am besten charakterisierte Enzym der PARP-Familie, ermittelt.   
Die Verminderung der PARP-1 Proteinmenge in Fibroblasten von der Maus 
wurde mittels zweier unterschiedlicher Techniken von RNAi getestet. Die erste 
Methode basiert auf der Verwendung von DNA Plasmiden. Unter der Kontrolle von 
Polymerase III Promotoren werden die siRNA Moleküle in den Zellen exprimiert. Auf 
der einen Seite ist diese Methode sehr arbeitsintensiv, andererseits hat sie den 
Vorteil, dass der RNAi Effekt über eine längere Zeitperiode erreicht werden kann. Der 
Hauptnachteil dieser Methode ist jedoch, dass der Erfolg von der 
Transfektionseffizienz der DNA Plasmide abhängig ist. Die zweite Methode, die in 
dieser Studie verwendet wurde, basiert auf der direkten Transfektion von in vitro 
hergestellter siRNA; siRNA Moleküle können leicht in Säugetierzellen transfiziert 
werden, haben aber auf der anderen Seite den Nachteil, dass nur ein zeitlich 
begrenzter RNAi Effekt erzielt werden kann.  
Hinsichtlich der ersten Methode wurden drei Sequenzen, die unterschiedliche 
Regionen im PARP-1 Gen kodieren, in den pSilencer 1.0-U6 Vektor (pSU6) 
eingebaut und mit Hilfe von verschiedenen chemischen Methoden in 
Mausfibroblasten transfiziert. Zudem wurde ein Plasmid, das siRNA Moleküle 
exprimiert, die spezifisch für das glykolytische Enzym GAPDH sind, als positive 
Kontrolle verwendet. Wie mittels Immunoblotting gezeigt werden konnte, wurde mit 
diesem System weder eine ausreichende Verminderung der PARP-1 Protein Menge, 
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noch derjenigen von GAPDH, erreicht. Auf der Basis einer unabhängigen Serie von 
Versuchen, bei denen ein GFP-p53 Expressionsvektor chemisch in Fibroblasten von 
der Maus transfiziert wurden, konnte das Ausbleiben des Gen-Silencing auf niedrige 
Transfektionsraten zurückgeführt werden. Höhere Raten dagegen zeigte die 
Transfektion mittels Elektroporation. Bei Verwendung dieser Technik nahmen 40 % 
der Zellen das Plasmid auf und exprimierten GFP-p53. Dementsprechend konnte 
eine 40-50 %ige Verminderung der zellulären GAPDH Menge durch Elektroporation 
des spezifischen siRNA-pSU6 Konstrukts erreicht werden.  
Im Hinblick auf die zweite Methode wurden sechs siRNAs Sequenzen aus der 
DNA-Bindungsdomäne von PARP-1 in vitro synthetisiert und auf ihr Vermögen die 
PARP-1 Expression zu vermindern hin untersucht. Immunoblot Analysen zeigten, 
dass die siRNA Moleküle, die für verschiedene Positionen auf der mRNA von 
PARP-1 kodieren, in der Lage waren, die PARP-1 Expression von 35 % bis mehr als 
98 % der ursprünglichen Level zu reduzieren. Der Effekt wurde nach 24 Stunden 
sichtbar und hielt bis mindestens 72 Stunden nach der Transfection an. 
Wie erwartet und in Übereinstimmung mit Daten von Knockout Mäusen zeigte 
das posttranskriptionale Silencing von PARP-1 mittels RNAi unter normalen 
Wachstumsbedingungen keinen offensichtlichen Phenotyp; jedoch waren die mit 
siRNA behandelten Zellen resistenter gegenüber oxidativem Stress als die Wildtyp 
Zellen. 
Die vorliegende Studie zeigt die notwendigen Bedingungen für ein effizientes 
Silencing von PARP-1 in Zellkulturen; diese Methode wird die Basis für weitere 
Untersuchungen sein, die letztendlich zur Identifikation der Funktion von PARP-1, 
und mehr allgemein, zur Funktion der Poly(ADP-Ribose) Synthese, als Antwort auf 
DNA Schäden, führen. Das erworbene Wissen wird das Identifizieren und die 
Herstellung von siRNA Molekülen, die die weiteren Mitglieder der PARP Familie 
kodieren, stark erleichtern.  
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